OS rates from second-line treatment to end of follow-up or death from any cause by age and time to second-line treatment
| . | 2-year survival (95% CI), % . | 5-year survival (95% CI), % . |
|---|---|---|
| Age, y | ||
| 18-60 | 43 (39-48) | 38 (33-42) |
| 60-69 | 33 (28-37) | 27 (23-32) |
| 70-79 | 29 (25-34) | 16 (12-21) |
| ≥80 | 20 (15-25) | 12 (7-17) |
| Time to second-line treatment, y | ||
| <1 | 32 (29-36) | 28 (25-32) |
| 1-2 | 52 (41-61) | 36 (25-47) |
| ≥2 | 60 (51-68) | 54 (44-63) |
| . | 2-year survival (95% CI), % . | 5-year survival (95% CI), % . |
|---|---|---|
| Age, y | ||
| 18-60 | 43 (39-48) | 38 (33-42) |
| 60-69 | 33 (28-37) | 27 (23-32) |
| 70-79 | 29 (25-34) | 16 (12-21) |
| ≥80 | 20 (15-25) | 12 (7-17) |
| Time to second-line treatment, y | ||
| <1 | 32 (29-36) | 28 (25-32) |
| 1-2 | 52 (41-61) | 36 (25-47) |
| ≥2 | 60 (51-68) | 54 (44-63) |